Biomarin Pharmaceutical Inc
1BMRN
Company Profile
Business description
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Contact
770 Lindaro Street
San RafaelCA94901
USAT: +1 415 506-6700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3,040
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,456.20 | 90.50 | 1.08% |
| CAC 40 | 7,710.81 | 116.94 | 1.54% |
| DAX 40 | 22,901.10 | 404.12 | 1.80% |
| Dow JONES (US) | 40,752.96 | 83.60 | 0.21% |
| FTSE 100 | 8,567.01 | 70.21 | 0.83% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,710.74 | 264.40 | 1.52% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,327.89 | 179.29 | 1.48% |
| S&P 500 | 5,604.14 | 35.08 | 0.63% |
| S&P/ASX 200 | 8,238.00 | 92.40 | 1.13% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |